How does 7808's PB Ratio compare to its peers?

7808 is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (3.2x).

How does 7808's PB Ratio compare vs other companies in the TW Biotechs Industry?

7808 is good value based on its Price-To-Book Ratio (3.6x) compared to the TW Biotechs industry average (3.6x).

What is 7808's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 7808's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 7808 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 7808's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

7808 Stock Overview

A biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. More details

7808 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue grew by 1527.4% over the past year

Risk Analysis

Shares are highly illiquid

Does not have meaningful revenue (NT$43M)

My Notes

Capture your thoughts, links and company narrative

BIONET Therapeutics Corp. Competitors

TCM Biotech International

TPEX:4169

NT$3.4b

Shine-On BioMedicalLtd

TPEX:6926

NT$3.4b

BRIM Biotechnology

TWSE:6885

NT$3.7b

TaiRx

TPEX:6580

NT$2.8b

Price History & Performance

Summary of share price highs, lows and changes for BIONET Therapeutics
Historical stock prices
Current Share Price	NT$46.75
52 Week High	NT$72.60
52 Week Low	NT$42.40
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-14.22%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	7808	TW Biotechs	TW Market
7D	-2.0%	-0.6%	-1.8%
1Y	n/a	4.3%	27.9%

Return vs Industry: Insufficient data to determine how 7808 performed against the TW Biotechs industry.

Return vs Market: Insufficient data to determine how 7808 performed against the TW Market.

Price Volatility

Is 7808's price volatile compared to industry and market?
7808 volatility
7808 Average Weekly Movement	n/a
Biotechs Industry Average Movement	4.5%
Market Average Movement	4.4%
10% most volatile stocks in TW Market	7.8%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 7808's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: Insufficient data to determine 7808's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2022	n/a	n/a	www.bionettx.com

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides CRDMO services.

BIONET Therapeutics Corp. Fundamentals Summary

How do BIONET Therapeutics's earnings and revenue compare to its market cap?
7808 fundamental statistics
Market cap	NT$3.36b
Earnings (TTM)	-NT$54.31m
Revenue (TTM)	NT$43.33m

75.5x

P/S Ratio

-60.3x

P/E Ratio

Is 7808 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7808 income statement (TTM)
Revenue	NT$43.33m
Cost of Revenue	NT$39.95m
Gross Profit	NT$3.38m
Other Expenses	NT$57.69m
Earnings	-NT$54.31m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.78
Gross Margin	7.79%
Net Profit Margin	-125.34%
Debt/Equity Ratio	0%

How did 7808 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/03 10:05
End of Day Share Price	2025/01/03 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BIONET Therapeutics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution